基于肠促胰素治疗的药物比较：GLP-1类似物利拉鲁肽的临床优势  

Comparison of incretin-based drugs： clinical advantage of GLP-1 analogue iiraglutide

作　　者：母义明[1] 

机构地区：[1]解放军总医院内分泌科,北京100853

出　　处：《中华内分泌代谢杂志》2012年第9期I0009-I0012,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：胰升糖素样肽1（GLP-1）受体激动剂和二肽基肽酶4（DPP-4）抑制剂是基于肠促胰素治疗2型糖尿病的2类药物，GLP-1受体激动剂可直接激活GLP-1受体，而DPP-4抑制剂通过阻止肠促胰素的酶降解间接发挥作用，二者在临床应用方面的比较是研究的热点。一项头对头比较研究表明，与DPP-g抑制剂西格列汀相比，GLP-1类似物利拉鲁肽降糖、减轻体重和改善p细胞功能的作用更为明显，同时患者的治疗满意度更高，在药物经济学上成本效益更优。利拉鲁肽的这些优势为2型糖尿病患者的临床治疗提供了新的理想选择。Glucagon-like peptide 1 （ GLP-I ） receptor agonists and dipeptidyl peptidase-d （DPP4） inhibitors are two elasses of incretin-based drugs for type 2 diabetes treatment. GLP-1 receptor agonists can directly activate the GLP-1 receptor while DPP-4 inhibitors act indirectly via preventing incretin enzymatic degradation. The comparison of two classes of drugs in clinical use becomes a hot research topic. A head to head comparison study has shown that, compared with DPP-4 inhibitor sitagliptin, GLP-1 analogue liraglutide shows better blood glucose control, weight loss, and β-cell fanction improvement, as well as higher patient treatment satisfaction and better costeffectiveness of drug economics. Those advantages of liraglutide provide an ideal choice for the clinical treatment of patients with type 2 diabetes.

关 键 词：肠促胰素 利拉鲁肽 西格列汀 糖尿病 2型 

分 类 号：R587.1[医药卫生—内分泌]